Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
ALBO Stock Summary
In the News
Is Albireo Pharma (ALBO) Stock Outpacing Its Medical Peers This Year?
Here is how Albireo Pharma (ALBO) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year.
Albireo Pharma: Elucidating The Ipsen Buyout (Rating Upgrade)
Albireo Pharma, Inc. has entered into an agreement to get acquired by Ipsen. Bylvay is already approved for PFIC. Nevertheless, the stellar drug is poised to gain additional labels for Alagille syndrome and biliary atresia.
2 Tiny Nasdaq Stocks Making Major Merger Moves Monday
The market is moving higher, and these small companies are helping.
Albireo Pharma, Inc. (ALBO) Q3 2022 Earnings Call Transcript
Albireo Pharma, Inc. (NASDAQ:ALBO ) Q3 2022 Results Conference Call November 8, 2022 4:30 PM ET Company Participants Hans Vitzthum - Managing Director, LifeSci Advisors Ron Cooper - President and Chief Executive Officer Jan Musin - Chief Scientific Officer, Head of R&D Pamela Stephenson - Chief Commercial Officer Simon Harford - Chief Financial Officer Conference Call Participants Miriam Nolan - Jefferies Brian Skorney - Baird Ritu Baral - Cowen Seamus Fernandez - Guggenheim Tim Lugo - William Blair Andreas Argyrides - Wedbush Securities Thomas Yip - H. C. Wainwright Operator Good afternoon.
Albireo Pharma (ALBO) Reports Q3 Loss, Tops Revenue Estimates
Albireo Pharma (ALBO) delivered earnings and revenue surprises of -1.61% and 1.58%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Albireo to Present Late Breaking Bylvay® (odevixibat) Data at AASLD 2022
– Oral late breaker with new results from positive Phase 3 ASSERT study in Alagille syndrome (ALGS)
Albireo to Report Q3 2022 Financial Results on November 8, 2022
Conference call and webcast to be held at 4:30 pm ET Conference call and webcast to be held at 4:30 pm ET
Albireo: Strong Phase 3 Data Foretells More Upside
Sales for Bylvay's first approved indication is increasing. The company recently posted superb data for an orphan disease known as Alagille Syndrome.
Albireo (ALBO) Up on Results From Alagille Syndrome Study
Albireo Pharma (ALBO) reports positive top-line data from a late-stage study evaluating Bylvay in Alagille syndrome. The study meets the primary and key secondary endpoint Stock up.
Albireo's stock is up 10% on plans to seek FDA approval for drug for rare disorder
Shares of Albireo Pharma Inc. ALBO, +6.86% gained 10.4% in premarket trading on Tuesday after the company said it is seeking Food and Drug Administration approval to use its medication Bylvay as a treatment for Alagille syndrome, a rare inherited disorder that can result in liver damage. Albireo said a Phase 3 clinical trial evaluating the drug met its primary endpoint and a key secondary endpoint.
ALBO Financial details
ALBO Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 1.09 | 0.77 | 0.52 | 2.11 | |
Net income per share | -3.12 | -3.94 | -5.77 | -7.45 | -7.87 | |
Operating cash flow per share | -3.53 | -2.29 | -4.25 | -6.32 | -5.6 | |
Free cash flow per share | -3.55 | -2.3 | -4.3 | -6.33 | -5.62 | |
Cash per share | 6.81 | 14 | 10.6 | 15.72 | 12.91 | |
Book value per share | 8.35 | 10.48 | 7.49 | 11.34 | 9.14 | |
Tangible book value per share | 6.14 | 9 | 6.1 | 10.26 | 8.24 | |
Share holders equity per share | 8.35 | 10.48 | 7.49 | 11.34 | 9.14 | |
Interest debt per share | 0.01 | -0.41 | 0.43 | 1.31 | 1.25 | |
Market cap | 200.17M | 287.07M | 316.17M | 599.52M | 447.65M | |
Enterprise value | 146.94M | 123.18M | 184.32M | 357.87M | 209.55M | |
P/E ratio | -8.2 | -6.23 | -4.41 | -5.04 | -2.96 | |
Price to sales ratio | 200.17K | 22.53 | 32.81 | 72.16 | 11.03 | |
POCF ratio | -7.26 | -10.71 | -5.97 | -5.93 | -4.16 | |
PFCF ratio | -7.21 | -10.69 | -5.91 | -5.93 | -4.14 | |
P/B Ratio | 3.07 | 2.34 | 3.39 | 3.31 | 2.55 | |
PTB ratio | 3.07 | 2.34 | 3.39 | 3.31 | 2.55 | |
EV to sales | 146.94K | 9.67 | 19.13 | 43.08 | 5.16 | |
Enterprise value over EBITDA | -5.99 | -3.25 | -3.22 | -3.72 | -10.57 | |
EV to operating cash flow | -5.33 | -4.6 | -3.48 | -3.54 | -1.95 | |
EV to free cash flow | -5.29 | -4.59 | -3.45 | -3.54 | -1.94 | |
Earnings yield | -0.12 | -0.16 | -0.23 | -0.2 | -0.34 | |
Free cash flow yield | -0.14 | -0.09 | -0.17 | -0.17 | -0.24 | |
Debt to equity | 0 | 0 | 0 | 0.05 | 0.06 | |
Debt to assets | 0 | 0 | 0 | 0.03 | 0.03 | |
Net debt to EBITDA | 2.17 | 4.33 | 2.3 | 2.52 | 12.01 | |
Current ratio | 6.94 | 13.07 | 7.49 | 10.36 | 5.93 | |
Interest coverage | -614.43 | 7.83 | -11.54 | -8.47 | -8.86 | |
Income quality | 1.13 | 0.58 | 0.84 | 0.94 | 3.16 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 15.25K | 1.42 | 2.38 | 5.11 | 0 | |
Research and developement to revenue | 12.99K | 2.49 | 4.73 | 9.24 | 2.03 | |
Intangibles to total assets | 0.24 | 0.09 | 0.1 | 0.06 | 0.06 | |
Capex to operating cash flow | 0.01 | 0 | 0.01 | 0 | 0 | |
Capex to revenue | -190 | 0 | -0.06 | -0.01 | -0.01 | |
Capex to depreciation | -5.43 | -1.36 | -4.25 | -0.41 | -1.7 | |
Stock based compensation to revenue | 3.7K | 0.44 | 0.79 | 1.76 | 0.39 | |
Graham number | 24.21 | 30.48 | 31.17 | 43.58 | 40.23 | |
ROIC | -0.38 | -0.31 | -0.75 | -0.56 | -2.96 | |
Return on tangible assets | -0.44 | -0.27 | -0.49 | -0.44 | -0.53 | |
Graham Net | 5.86 | 8.82 | 4.82 | 9.19 | 6.46 | |
Working capital | 47.08M | 154.83M | 122.88M | 236.58M | 223.58M | |
Tangible asset value | 47.99M | 105.38M | 75.9M | 163.97M | 158.35M | |
Net current asset value | 47.04M | 104.82M | 69.89M | 157.49M | 142.49M | |
Invested capital | 0 | 0 | 0 | 0.05 | 0.06 | |
Average receivables | 548K | 1.82M | 1.46M | 0 | 1.64M | |
Average payables | 1.16M | 2.85M | 4.57M | 5.03M | 5.9M | |
Average inventory | 0 | 0 | 0 | 0 | 97K | |
Days sales outstanding | 264.99K | 83.51 | 0 | 0 | 29.43 | |
Days payables outstanding | 0 | 0 | 790.28 | 0 | 1.75K | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 52.22 | |
Receivables turnover | 0 | 4.37 | 0 | 0 | 12.4 | |
Payables turnover | 0 | 0 | 0.46 | 0 | 0.21 | |
Inventory turnover | 0 | 0 | 0 | 0 | 6.99 | |
ROE | -0.37 | -0.38 | -0.77 | -0.66 | -0.86 | |
Capex per share | -0.02 | -0.01 | -0.04 | 0 | -0.02 |
Quarterly Fundamentals Overview
Last date of statement is 2022-09-30 for Q3
Metric | History | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.19 | 1.69 | 0.35 | 0.42 | 0.5 | |
Net income per share | 2.96 | -0.57 | -2.34 | -2.18 | -1.95 | |
Operating cash flow per share | -1.43 | -0.72 | -1.83 | -1.86 | -1.51 | |
Free cash flow per share | -1.44 | -0.73 | -1.84 | -1.89 | -1.51 | |
Cash per share | 13.64 | 12.86 | 11.18 | 9.24 | 11.32 | |
Book value per share | 9.44 | 9.1 | 7.65 | 5.8 | 5.09 | |
Tangible book value per share | 8.54 | 8.21 | 6.76 | 4.92 | 4.21 | |
Share holders equity per share | 9.44 | 9.1 | 7.65 | 5.8 | 5.09 | |
Interest debt per share | 0.69 | 0.69 | 0.67 | 0.66 | 0.13 | |
Market cap | 600.88M | 449.26M | 578.09M | 388.96M | 380.53M | |
Enterprise value | 348.19M | 211.16M | 371.52M | 218.15M | 158.05M | |
P/E ratio | 2.63 | -10.25 | -3.19 | -2.28 | -2.48 | |
Price to sales ratio | 164 | 13.81 | 84.62 | 47.4 | 38.7 | |
POCF ratio | -21.86 | -32.34 | -16.33 | -10.69 | -12.84 | |
PFCF ratio | -21.72 | -31.71 | -16.22 | -10.49 | -12.83 | |
P/B Ratio | 3.31 | 2.56 | 3.9 | 3.42 | 3.8 | |
PTB ratio | 3.31 | 2.56 | 3.9 | 3.42 | 3.8 | |
EV to sales | 95.03 | 6.49 | 54.38 | 26.58 | 16.08 | |
Enterprise value over EBITDA | 5.42 | -18.54 | -9.42 | -5.88 | -4.58 | |
EV to operating cash flow | -12.67 | -15.2 | -10.49 | -5.99 | -5.33 | |
EV to free cash flow | -12.58 | -14.9 | -10.42 | -5.88 | -5.33 | |
Earnings yield | 0.1 | -0.02 | -0.08 | -0.11 | -0.1 | |
Free cash flow yield | -0.05 | -0.03 | -0.06 | -0.1 | -0.08 | |
Debt to equity | 0.05 | 0.06 | 0.07 | 0.09 | 0 | |
Debt to assets | 0.03 | 0.03 | 0.04 | 0.04 | 0 | |
Net debt to EBITDA | -3.93 | 20.91 | 5.24 | 4.6 | 6.44 | |
Current ratio | 8.2 | 5.93 | 7.26 | 4.49 | 6.32 | |
Interest coverage | 19.28 | -3.53 | -13.75 | -13.55 | -13.7 | |
Income quality | -0.48 | 1.27 | 0.83 | 0.91 | 0.78 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0.99 | 0 | 0 | 0 | |
Research and developement to revenue | 5.75 | 0.63 | 3.21 | 2.79 | 2.37 | |
Intangibles to total assets | 0.06 | 0.06 | 0.07 | 0.08 | 0.05 | |
Capex to operating cash flow | 0.01 | 0.02 | 0.01 | 0.02 | 0 | |
Capex to revenue | -0.05 | -0.01 | -0.03 | -0.08 | 0 | |
Capex to depreciation | -2.02 | -2.61 | -2.06 | -8.15 | -0.32 | |
Stock based compensation to revenue | 1.83 | 0.08 | 0.51 | 0.44 | 0.36 | |
Graham number | 25.09 | 10.79 | 20.06 | 16.87 | 14.96 | |
ROIC | 0.31 | -0.05 | -0.27 | -0.32 | -0.35 | |
Return on tangible assets | 0.2 | -0.04 | -0.19 | -0.2 | -0.13 | |
Graham Net | 7.73 | 6.44 | 5.44 | 3.48 | 0.22 | |
Working capital | 238.75M | 223.58M | 197.22M | 152.16M | 201.02M | |
Tangible asset value | 164.46M | 158.35M | 130.93M | 96.42M | 82.81M | |
Net current asset value | 157.17M | 142.49M | 115.65M | 80.42M | 17.69M | |
Invested capital | 0.05 | 0.06 | 0.07 | 0.09 | 0 | |
Average receivables | 653.5K | 2.29M | 2.27M | 1.56M | 1.94M | |
Average payables | 6.46M | 6.87M | 6.44M | 5.88M | 6.17M | |
Average inventory | 98K | 195K | 1.01M | 1.96M | 2.62M | |
Days sales outstanding | 32.1 | 9.06 | 16.8 | 20.28 | 18.57 | |
Days payables outstanding | 1.51K | 633.99 | 2.45K | 625.59 | 1.02K | |
Days of inventory on hand | 40.93 | 18.88 | 700.38 | 243.09 | 463.09 | |
Receivables turnover | 2.8 | 9.94 | 5.36 | 4.44 | 4.85 | |
Payables turnover | 0.06 | 0.14 | 0.04 | 0.14 | 0.09 | |
Inventory turnover | 2.2 | 4.77 | 0.13 | 0.37 | 0.19 | |
ROE | 0.31 | -0.06 | -0.31 | -0.38 | -0.38 | |
Capex per share | -0.01 | -0.01 | -0.01 | -0.03 | 0 |
ALBO Frequently Asked Questions
What is Albireo Pharma, Inc. stock symbol ?
Albireo Pharma, Inc. is a US stock , located in Boston of Ma and trading under the symbol ALBO
Is Albireo Pharma, Inc. buy or a sell ?
3 stock analysts have 3 predictions with a medium analyst target price of $44. The lowest prediction is $42 and the highest is $48
What is ALBO stock prediction ?
What is Albireo Pharma, Inc. stock quote today ?
Albireo Pharma, Inc. stock price is $44.15 today.
Is Albireo Pharma, Inc. stock public?
Yes, Albireo Pharma, Inc. is a publicly traded company.